Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Dec;250(6):462-75.
doi: 10.1046/j.1365-2796.2001.00911.x.

Progress in the development of immunotherapy for the treatment of patients with cancer

S A Rosenberg  1
Affiliations
Review

Progress in the development of immunotherapy for the treatment of patients with cancer

S A Rosenberg. J Intern Med. 2001 Dec.

Abstract

Several recent developments have hallmarked progress in tumour immunology and immunotherapy. The use of interleukin-2 (IL-2) in cancer patients demonstrated that an immunological manipulation was capable of mediating the regression of established growing cancers in humans. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing patients against these antigens has opened important new avenues of exploration for the development of effective active and cell-transfer immunotherapies for patients with cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Actuarial analysis of the duration of response in patients with metastatic kidney cancer and metastatic melanoma who experienced a complete response after treatment with high-dose interleukin-2.
Fig. 2
Fig. 2
Example of a complete response of lung metastases in a patient with melanoma treated with interleukin-2, (left) Pretreatment, (right) post-treatment.
Fig. 3
Fig. 3
Example of the regression of a liver metastasis in a patient with renal cancer treated with interleukin-2, (upper) pretreatment, (lower) post-treatment.
Fig. 4
Fig. 4
Example of regression of a bony metastasis in the right pubic ramus in a patient with renal cancer treated with interleukin-2 plus LAK cells, (upper) pretreatment, (lower) post-treatment.
Fig. 5
Fig. 5
Regression of multiple cutaneous metastases in a patient with melanoma treated with interleukin-2 plus LAK cells, (left) pretreatment, (right) post-treatment.
Fig. 6
Fig. 6
Recognition by multiple clones reactive with the gp100: 209–217 peptide from a patient immunized with the gp100: 209–217 (210M) peptide.
See this image and copyright information in PMC

References

    1. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T-lymphocytes from normal bone marrow. Science. 1986;193:1007. - PubMed
    1. Rosenberg SA, Schwarz S, Spiess PJ. In vitro growth of murine T-cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. J Immunol. 1978;121:1951. - PubMed
    1. Strausser JL, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J Immunol. 1978;121:1491. - PubMed
    1. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor (TCGF) Cancer Res. 1981;41:4420. - PubMed
    1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. The lymphokine activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. - PMC - PubMed

MeSH terms